Clinical Policy: Clobazam (Onfi, Sympazan)

Reference Number: MDN.CP.PMN.54
Effective Date: 4.1.24
Last Review Date: 2.14.24
Line of Business: Medicaid

Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

Clobazam (Onfi®, Sympazan®) is a benzodiazepine.

FDA Approved Indication(s)

Onfi and Sympazan are indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Onfi and Sympazan are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Lennox-Gastaut Syndrome (must meet all)**:**

1. Diagnosis of LGS;
2. Age ≥ 2 years;
3. Dose does not exceed 40 mg per day (2 tablets per day, 16 mL per day, or 2 films per day).

Approval duration: 12 months

B. Intractable/Refractory Epilepsy (off-label) (must meet all)**:**

1. Diagnosis of intractable/refractory epilepsy;
   Prescribed by or in consultation with a neurologist;
2. Age ≥ 2 years;
3. For Onfi and Sympazan requests, member must useuse generic clobazam tablets and oral suspension (e.g., contraindications to excipients in generic formulations);
4. Dose does not exceed 40 mg per day (2 tablets per day, 16 mL per day, or 2 films per day).

Approval duration: 12 months

C. Dravet Syndrome (off-label) (must meet all)**:**

1. Diagnosis of Dravet syndrome;
2. Prescribed by or in consultation with a neurologist;

3. Age ≥ 2 years;
4. For Onfi and Sympazan requests, member must use generic clobazam tablets and oral suspension (e.g., contraindications to excipients in generic formulations);
5. Dose does not exceed 2 mg/kg per day.

Approval duration: 12 months

D. Other diagnoses/indications (must meet 1 or 2):
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
   a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
   b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all)**:**
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Onfi or Sympazan for Lennox-Gastaut syndrome, intractable/ refractory epilepsy, or Dravet syndrome and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed one of the following (a or b):
   a. LGS or intractable/refractory epilepsy: 40 mg per day (2 tablets per day, 16 mL per day, or 2 films per day);
   b. Dravet syndrome: 2 mg/kg per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
   a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
   b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid

.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration
LGS: Lennox-Gastaut syndrome

Appendix B: Contraindications/Boxed Warnings

- Contraindication(s): history of hypersensitivity to the drug or its ingredients
- Boxed warning(s): risks from concomitant use with opioids; abuse, misuse, and addiction; dependence and withdrawal reactions

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
LGS	Patients ≤ 30 kg body weight: initiate at 5 mg PO daily and titrate as tolerated up to 20 mg daily Patients > 30 kg body weight: initiate at 10 mg PO daily and titrate as tolerated up to 40 mg daily A daily dose of Onfi greater than 5 mg should be administered in divided doses twice daily; a 5 mg daily dose can be administered as a single dose.	≤ 30 kg body weight: 20 mg/day > 30 kg body weight: 40 mg/day
Intractable/refractory epilepsy (off-label)	See LGS	See LGS
Dravet syndrome (off-label)	Initial: 0.2-0.3 mg/kg/day PO Maximum: 0.5-2 mg/kg/day PO	See regimen

VI. Product Availability

Drug Name	Availability
Clobazam (Onfi)	Tablet with a functional score: 10 mg, 20 mg Oral suspension: 2.5 mg/mL in 120 mL bottles
Clobazam (Sympazan)	Oral film: 5 mg, 10 mg, 20 mg

VII. References

1. Onfi Prescribing Information. Deerfield, IL: Lundbeck; February 2020. Available at: https://www.onfihcp.com/. Accessed August 20, 2021..
2. Sympazan Prescribing Information. Warren, NJ: Aquestive Therapeutics; March 2021. Available at: www.sympazan.com. Accessed August 20, 2021.
3. Hancock EC, Cross JH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2013 Feb 28;(2).
4. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009 Jan;8(1):82-93.
5. Mills JK, Lewis TG, Mughal K, et al. Retention rate of clobazam, topiramate and lamotrigine in children with intractable epilepsies at 1 year. Seizure. 2011 June;20(5): 402-405.
6. Gauthier AC, Mattson RH. Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy. CNS Neurosci Ther. 2015 Jul;21(7):543-8.
7. Montenegro MA, Arif H, Nahm EA, et al. Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center. Clin Neuropharmacol. 2008 NovDec;31(6):333-8.
8. Cross JH, Auvin S, Falip M, et al. Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations. Frontiers in Neurology. 2017;8:505.
9. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2018. Available at: http://www.clinicalpharmacology-ip.com/. Accessed August 420, 2021.
10. Wirrell EC, Laux L, Jette N, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017; 68: 18-34.
11. Epilepsies: diagnosis and management. National Institute for Health and Care Excellence (NICE) website. https://www.nice.org.uk/guidance/CG137/chapter/Appendix-EPharmacological-treatment. Updated April 2018. Accessed August 22, 2018.
12. Wirrell EC. Treatment of Dravet syndrome. Can J Neurol Sci. 2016; 43 Suppl 3: S13-8. doi: 10.1017/cjn.2016.249. https://www.ncbi.nlm.nih.gov/pubmed/27264138.
13. Practice Guideline Update: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy. American Academy of Neurology. Available at: https://www.aan.com/Guidelines/Home/GetGuidelineContent/922. Accessed July 25, 2019.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
New policy created, from IL.PMN.54 Clobazam (Onfi) policy per HFS regulation	2.14.24	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional

organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

For Health Insurance Marketplace members, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the formulary exception policy.